Citadel Advisors
VOR icon

Citadel Advisors’s Vor Biopharma VOR Stock Holding History

Citadel Advisors’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,165
Closed -$211K – 14333
2025
Q4 		$211K Buy
16,165
+1,045
+7% +$19.5K ﹤0.01% 10927
2025
Q3 		$737K Sell
15,120
-22,725
-60% -$914K ﹤0.01% 8224
2025
Q2 		$1.23M Buy
+37,845
New +$334K ﹤0.01% 6654
2025
Q1 		– Sell
-1,045
Closed -$23.2K – 15649
2024
Q4 		$23.2K Buy
1,045
+580
+125% +$9.61K ﹤0.01% 13083
2024
Q3 		$6.51K Buy
465
+390
+520% +$7.11K ﹤0.01% 13416
2024
Q2 		$1.5K Sell
75
-15
-17% -$485 ﹤0.01% 13808
2024
Q1 		$4.27K Sell
90
-80
-47% -$3.51K ﹤0.01% 13828
2023
Q4 		$7.65K Sell
170
-140
-45% -$5.78K ﹤0.01% 13275
2023
Q3 		$13.1K Buy
310
+195
+170% +$10.6K ﹤0.01% 12934
2023
Q2 		$7.11K Sell
115
-785
-87% -$71.7K ﹤0.01% 13389
2023
Q1 		$96.8K Sell
900
-290
-24% -$32.1K ﹤0.01% 11311
2022
Q4 		$158K Buy
+1,190
New +$118K ﹤0.01% 10530

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's VOR Position: Q1 2026 in Review

Citadel Advisors reduced its Vor Biopharma (VOR) stake by 66% in Q1 2026, selling an estimated $4.02M and leaving 148,768 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #5503.

Citadel Advisors first reported a position in VOR in Q4 2021 and has held it in 16 quarters since. The position peaked at $5.68M in Q4 2025. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Citadel Advisors held 148,768 shares of Vor Biopharma worth $2.65M as of Q1 2026.
  • Citadel Advisors sold 285,126 Vor Biopharma shares in Q1 2026, an estimated $4.02M.
  • Vor Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5503 holding.
  • Citadel Advisors first reported a position in Vor Biopharma in Q4 2021 and has held it in 16 quarters since.
  • Citadel Advisors's Vor Biopharma position peaked at $5.68M in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.